NCT06515470View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

July 3, 2024

Primary Completion Date

September 30, 2027

Study Completion Date

December 31, 2027

Conditions
Breast Cancer
Interventions
DRUG

BTX-9341

Daily oral dose in 28-day cycles until maximum tolerated dose (MTD) or maximum evaluable dose (MED) determined

DRUG

Fulvestrant

500 mg intramuscular injections on Day 15 and then every 28 days

DRUG

BTX-9341

Daily oral dose in 28-day cycles using dose determined in Part A

Trial Locations (6)

22031

RECRUITING

Biotheryx Investigative Site, Fairfax

55905

RECRUITING

Biotheryx Investigative Site, Rochester

68130

RECRUITING

Biotheryx Investigative Site, Omaha

77030

RECRUITING

Biotheryx Investigative Site, Houston

78229

RECRUITING

Biotheryx Investigative Site, San Antonio

84119

RECRUITING

Biotheryx Investigative Site, West Valley City

All Listed Sponsors
lead

Biotheryx, Inc.

INDUSTRY